Fund roundup July 2014

Important Information

We want to make investing with us simple and straightforward for all of our clients.

Please select your investor type from the options below.

Alternatively you can register or log in to an existing account.

Please note that by making your selection here you are agreeing to the Woodford Investment Management Ltd Privacy Statement and to our Terms and Conditions.

Mitchell Fraser-Jones 5 August 2014 Est. reading: 5 min read

The UK stock market posted a small negative return during July. Having moved broadly sideways all year so far, the market took a nervous step downwards in the last couple of days of July in a move that has continued thus far into August. It isn’t a drastic move, in the context of some that we have seen in recent years, but equity markets have lacked volatility this year and a feeling of complacency appears to have crept into some parts of the market.

Source: Bloomberg in capital return terms to 4 August 2014.

We have been a bit surprised by the market’s lack of concern about some of the geopolitical events that have been brewing in the background – the unrest in Ukraine / Russia and Israel / Gaza, for example, initially shrugged off by the market, but in recent days the market seems to have become, quite rightly, a bit more concerned. These issues are not positive for an already troubled global economic outlook and do not look easy to resolve.

The fund reported a very slight increase in price during the month of July in contrast to the market’s slight decline. However, one month is a very short time period to be analysing a long-term investment strategy in an asset class that really needs to be judged in periods of years rather than months.

The fund’s performance was negatively impacted by a disappointing set of financial results from GlaxoSmithKline, the fund’s second biggest holding. In particular, a poor performance from its respiratory franchise, led to revenue, profit and earnings all declining and missing consensus expectations by some margin.  It did, however, meet expectations with its dividend, announcing a 6% increase in its Q2 dividend of 19p per share. A long conversation with Glaxo’s Chief Executive post results has allowed us to maintain confidence in the long term investment case, despite this near term setback. Glaxo remains a very cash generative business and it is a very cheap share in our view, with a starting yield of 5.5%* and the prospect of modest but sustainable long-term dividend growth. We bought a few more Glaxo shares towards the end of the month.

The negative impact from GlaxoSmithKline was partly mitigated by better performance elsewhere in the portfolio. Capita, for instance, performed well buoyed by very strong financial results which showed double-digit growth in revenue, profit, earnings and dividends. HSBC also performed robustly on no news.  A couple of our intellectual property commercialisation holdings also performed well during the month – Allied Minds and Imperial Innovations. The latter announced the successful IPO of one of its investments, Abzena, which raised £20m by issuing shares to new and existing shareholders, ourselves included, at 80p per share. Abzena is the fourth Imperial Innovations’ company to join the public market in recent months, demonstrating the strength in depth of its exciting and valuable portfolio.

The market greeted news of further consolidation in the tobacco sector somewhat negatively, which surprised us because we think it’s a great deal for all concerned. This is probably a case of it being better to travel than to arrive, however – the sector had a very strong run of performance in anticipation of the deal. Reynolds American, which has agreed to acquire Lorillard, was particularly weak but we think its good news for the company. It creates an opportunity for them to take a step forward in terms of scale, efficiency and brand portfolio strength. BAT also stands to benefit, being a 42% shareholder in Reynolds. The deal, if consummated, is expected to deliver a very attractive return on investment to Reynolds and enhance next year’s earnings by a mid-teens per cent.

The deal is also good news for Imperial Tobacco, which intends to buy some attractive brands that Reynolds / Lorillard need to sell for anti-trust reasons. This represents a great opportunity for Imperial Tobacco to improve the fortunes of its US business and, again, if consummated, is expected to deliver very attractive returns and earnings enhancements. This is a sector that has created considerable shareholder value through M&A in the past. Tobacco companies have done this by doing the right deals, at the right price, at the right time. We remain positive on the sector and bought more shares in each of the companies involved, focusing particularly on the opportunity to add to Imperial Tobacco and Reynolds American at the lower prices that prevailed after the deal had been announced. We did sell our holding in Altria though, which maintained the fund’s overall exposure to the sector at broadly the same level.

Elsewhere in terms of portfolio activity, we added several new holdings to the fund, the largest of which was Royal Mail. Since its IPO last year, the shares initially performed very strongly but have since come back to more attractive territory. This is fundamentally a very attractive, cash generative business. It has its challenges, not least the competitive threat in profitable, densely populated areas. But it has its opportunities too, such as slowly working to bring its cost base into line with its competitors. Royal Mail has an operating margin of 4.6% compared to 8-10% for most of its peers*. We have been impressed by the management team and believe it is well-placed to capitalise on the long-term opportunity to deliver a better service to its customers and generate sustainable shareholder value.

Other new holdings added during July included Oakley Capital, Raven Russia and we participated in the IPOs of Abzena (mentioned above) and Spire Healthcare. We increased exposure to several core holdings but Altria, Novartis and Serco exited the portfolio.

Our strategy and outlook for the fund remain unchanged. We see a challenging future for the global economy and indeed for equity markets in a world without artificial support from the Federal Reserve. Nevertheless, we have built the portfolio around attractively valued businesses that can deliver sustainable long-term growth in spite of the difficult economic environment. Hence, we are confident that the portfolio can, in turn, deliver attractively positive long-term returns.

* Source: Bloomberg as at 5 August 2014.

LF Woodford Equity Income Fund
Download as a PDF

What are the risks?

  • The value of the fund and any income from it may go down as well as up, so you may get back less than you invested
  • Past performance cannot be relied upon as a guide to future performance
  • The ongoing charges figure is charged to capital, so the income of the fund may be higher but capital growth may be restricted or capital may be eroded
  • The fund may invest in other transferable securities, money market instruments, warrants, collective investment schemes and deposits – some of these security types could increase the fund′s volatility and increase the level of indirect charges to which the fund is exposed
  • The fund may invest in overseas securities and be exposed to currencies other than pound sterling – as a result, exchange rate movements may cause the sterling value of investments to decrease or increase
  • The fund may invest in unquoted securities, which may be less liquid and more difficult to value, because they are generally not publicly traded – the lack of an open market may also make it more difficult to establish fair value

Important information

Before investing, you should read the Key Investor Information Document (KIID) for the fund, and the Prospectus which, along with our terms and conditions, can be obtained from the downloads page or from our registered office. If you have a financial adviser, you should seek their advice before investing. Woodford Investment Management Ltd is not authorised to provide investment advice.

The Woodford Funds (Ireland) ICAV (the “Fund”) has appointed as Swiss Representative Oligo Swiss Fund Services SA, Av. Villamont 17, 1005 Lausanne, Switzerland. The Fund′s Swiss paying agent is Neue Helvetische Bank AG. All fund documentation including, Prospectus, Key Investor Information Documents, Instrument of Incorporation and financial reports may be obtained free of charge from the Swiss Representative in Lausanne. The place of performance and jurisdiction for all shares distributed in or from Switzerland is at the registered office of the Swiss Representative. Fund prices can be found at

Woodford Investment Management Ltd is authorised and regulated by the Financial Conduct Authority (firm reference number 745433). Incorporated in England and Wales, company number 10118169. Registered address: 27 Old Gloucester Street, London, WC1N 3AX.

© 2019 Woodford Investment Management Ltd.
All rights reserved.

Are you sure?

By disagreeing you will no longer have access to our site and will be logged out.

Privacy Preference Center

Experience Tracking

Lets our analytics service track you across our different websites and enables data sharing among our different marketing tools.

AMCV_[Tracker ID]@AdobeOrg (Adobe), [Tracker ID]@AdobeOrg (Adobe)
Adobe Analytics (helps us provide you with more relevant experiences and content based on your likely interests). Cookies: demdex, dextp, dpm, DST, DSTJS
Twitter personalisation (by better understanding how devices are related, Twitter can use information from one device to help personalize the Twitter experience on another device). Cookies: personalization_id
Heap Analytics (provides metrics on user behaviour and actions throughout the site). Cookies: _gid, _hp2_id.[Tracker ID],_hp2_props.[Tracker ID], _ga, _mkto_trk, optimizelyBuckets, optimizelyEndUserId, optimizelySegments, raygun4js-userid, _attribution_referrer, _csrf
Adobe Analytics (provides you with more relevant experiences and marketing messages based on your likely interests). Cookies: _tmae ,ev_sync_dd,ev_sync_yh,everest_g_v2,gglck

Traffic Metrics

Allows Woodford to aggregate information on website usage and popular content

_ga, _gid
Google Analytics (tracks and reports website traffic and user behaviour): Cookie: CONSENT
New Relic (application and server performance monitoring – allows us to spot problems with our website code and improve them to keep things running smoothly). Cookie: JSESSIONID
Adobe Analytics (provides you with more relevant experiences and marketing messages based on your likely interests). Cookies: __qca,__smToken, _ga, _mkto_trk, _rtbmedia

Search History

Populates the 'recent searches' section of the website navigation.


Close your account?

Your account will be closed and all data will be permanently deleted and cannot be recovered. Are you sure?